Core Viewpoint - Edwards Lifesciences has forecasted 2026 profit above estimates, driven by strong demand for its artificial heart valves and other medical devices, resulting in a 3% increase in shares during after-hours trading [1] Group 1 - The company anticipates robust demand for its artificial heart valves and medical devices [1] - The positive forecast has led to a rise in the company's stock price by 3% in after-hours trading [1]

Core Insights - Edwards Lifesciences exceeded Wall Street expectations for third-quarter results, primarily due to robust demand for its artificial heart valves and other medical devices [1] Financial Performance - The company reported strong sales growth, contributing to a rise in share prices by approximately 3% following the announcement [1]